

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Heparlink Pharmaceutical Group Co., Ltd. (the **Company**), together with its subsidiary, the **Group**), in accordance with the Inside Information Provisions of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (**Listing Rules**).

The Board of Directors (the **Directors**) of the Company (the **Board**) is hereby notified of the Shareholders (the **Shareholders**) and the Italian Techdow Pharma S.R.L., a wholly owned subsidiary of the Company (**Techdow Italy**), is expected to have been defaulted by a criminal disclosure of an electrical fire in a factory in Italy on 11.7.2011 (the **Incident**). The Company has filed the Incident with the appropriate authorities and the police have been advised and the necessary criminal investigation is being carried out. The Company is fully cooperating with the police investigation and taking effective measures to prevent the Incident.

The management of the Company has immediately notified the Board, the Executive Director and the directors of the Incident, and the relevant authorities. The Board is aware of the Incident and is fully informed of the Incident. The Company is fully cooperating with the police investigation and the necessary criminal investigation is being carried out. The Company is fully cooperating with the police investigation and the necessary criminal investigation is being carried out.

The Board of Directors of the Company, having reviewed the TechLink IAL, has handled the IAL. After the investigation of the IAL in Guangzhou, the Board will, in accordance with the Company's financial policy, the effective date of 31 December 2023 (FY2023).

The Board is investigating the IAL in Guangzhou and will complete the investigation of the IAL as soon as possible.

The Board will handle the IAL in accordance with the Company's financial policy.

The Board will take the necessary measures to keep the Shareholders and the IAL informed of the investigation of the IAL. The Board will also advise the Board of the IAL in accordance with the Company's financial policy. The Board will also advise the Board of the IAL in accordance with the Company's financial policy. The Board will also advise the Board of the IAL in accordance with the Company's financial policy.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
January 15, 2024

As a reminder of his announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Y and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. L Chan, Mr. Hang Peng and Mr. Yi Ming.